Pfizer to Ship 4.5 Million Vaccine Doses to South Africa by June
(Bloomberg) --
Pfizer Inc. will ship 4.5 million doses of its Covid-19 vaccines to South Africa by June helping the nation ramp up its inoculation drive.
The first 325,260 doses will arrive Sunday night, Zweli Mkhize, South Africa's health minister said in a statement. The government also expects Johnson & Johnson to release stock from the Aspen Pharmacare Holdings Ltd.'s plant in the nation by the middle of May following a verification process with regulators, according to the statement. Aspen is making the J&J vaccines under license.
Read: South Africa's Spats With J&J, Pfizer Mask Patent Concerns
South Africa, which is the worst-affected country by the coronavirus pandemic on the continent, lags behind emerging market peers in vaccinations. It halted J&J vaccines after health agencies last month called for their suspension in the U.S. The J&J shot is a key element to the nation's vaccination plan and has already been used to inoculate health workers, with no reported adverse effects.
The government last month awarded tenders to state-backed Biologicals Vaccines Institute of Southern Africa Ltd. and Imperial Logistics Ltd. to import an unspecified quantity of doses, the Department of Health said in a document on its website. DSV Healthcare Ltd. was contracted to store and distribute the doses countrywide.
The government ordered 30 million of the two-dose vaccine developed by Pfizer and BioNTech SE, which in addition to the J&J shots should be sufficient to inoculate more than two thirds of the nation's 60 million population to achieve herd immunity.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.